December 10, 2013

Nearly all patients taking an experimental treatment for hepatitis C developed by AbbVie were cured, the drug maker said Tuesday.

December 6, 2013

The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

December 6, 2013

Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

November 25, 2013

The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

October 25, 2013

A Food and Drug Administration expert panel has recommended approval for a drug made by Johnson & Johnson for treating hepatitis C, the company said.

October 24, 2013

An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.

May 21, 2013

More evidence is emerging that interventions by pharmacists can have a profound beneficial effect on patient outcomes.

The latest example comes from Walgreens Specialty Pharmacy, which released the results of a study May 17 showing that more than two-thirds of patients with hepatitis C “achieved sustained virologic response or cure after completing newer ‘triple therapy’ treatment” backed up by a regimen of care and oversight by pharmacists, according to a Drug Store News report from senior editor Michael Johnsen.

Why the pharmacist interventions? They help improve patient compliance with the complicated drug therapy, which involves the administration of two newer protease inhibitors to prevent the HCV virus from reproducing, in combination with peginterferon and ribavirin. According to Johnsen, that powerful medicinal cocktail “significantly increased the cure rate and cut treatment time in half” for the 406 HCV patients in the study who received triple therapy with either telaprevir or boceprevir.

May 17, 2013

More than two-thirds of patients with hepatitis C achieved sustained virologic response or cure after completing newer “triple therapy” treatment, according to a Walgreens Specialty Pharmacy study released Friday.

May 6, 2013

An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

May 3, 2013

Actavis' had $1.9 billion in sales in first quarter 2013, the drug maker said.

April 5, 2013

Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.

April 4, 2013

The Food and Drug Administration approval this week of a generic genital herpes ointment made by Mylan could make a slight dent in the stock price of the company that makes the branded version.

April 3, 2013

The Food and Drug Administration has approved a new drug for genital herpes made by Mylan, the drug maker said.

February 19, 2013

Drug maker Gilead Sciences has recalled a single lot of an injected drug used to treat an opportunistic infection in AIDS patients due to the presence of foreign matter, the company said.

January 17, 2013

Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

June 14, 2012

Kadmon Pharmaceuticals earlier this month announced that it has launched a new 600 mg/day dose pack of Ribasphere RibaPak (ribavirin, USP), Kadmon's proprietary ribavirin regimen available in a daily, two-pill compliance package for enhanced therapy adherence.

April 20, 2012

Merck is testing two means of treating patients with chronic hepatitis C for anemia, a common side effect of certain treatments for the viral infection, the drug maker said.

September 6, 2011

Hemispherx Biopharma and Armada Health Care have entered a sales and marketing agreement for a drug designed to treat genital warts.

July 25, 2011

A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


July 19, 2011

The Food and Drug Administration has approved a drug made by Graceway Pharmaceuticals for actinic keratoses, Graceway said.

June 30, 2011

Canadian drug maker Valeant Pharmaceuticals International will acquire rights to topical drugs for eczema and cold sores from Swedish drug maker Meda.

June 16, 2011

Specialty pharmacy provider Axium Healthcare Pharmacy has introduced two recently approved hepatitis C drugs to its HepVisions therapy management program, the company said Thursday.

May 23, 2011

The Food and Drug Administration has approved a treatment for hepatitis C made by Vertex Pharmaceuticals, the agency said Monday.

May 23, 2011

The $290 billion that poor medication adherence costs the U.S. economy every year cuts across every imaginable disease state, but one in which it can be particularly problematic is mental health.